8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
Iterum Therapeutics plc(ITRM)Earnings, Financials & Key Ratios
ITRM•NASDAQ
$0.03
Price updated Jun 20, 2026
AboutIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$18M+59.7%
- Net Income-$25M+35.4%
- EPS (Diluted)-1.26+57.4%
ITRM Price & Volume
Iterum Therapeutics plc (ITRM) stock price & volume — 10-year historical chart
Loading chart...
Nascent Revenue Fails To Offset Solvency Risks
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary regulatory approval dependence
Key Thesis Takeaways
- Iterum Therapeutics is currently transitioning from a clinical-stage entity to a commercial-stage firm, evidenced by its initial $390.0K revenue in 2025Q3, yet the company remains burdened by a precarious financial structure.
- The firm faces significant solvency concerns as total debt of $33.7 million currently exceeds its total asset base of $32.5 million.
- Investors should remain cautious as the company's reliance on external financing to cover persistent quarterly net losses, such as the $9.0 million loss in 2025Q3, suggests a high-risk profile dependent on successful regulatory and market execution.
Verdict Logic
the company's precarious liquidity position, characterized by only $11.0 million in cash against $33.7 million in total debt, suggests substantial insolvency risk for long-term investors.
ITRM Growth Metrics
Iterum Therapeutics plc (ITRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM62.5%
Return on Capital
10 Years-111.69%
5 Years-85.94%
3 Years-91.11%
Last Year-94.11%
Peers Comparison
Key metrics vs top competitors for Iterum Therapeutics plc (ITRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.03 | $1.65M | -0.02 | — | — | — | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $2.16 | $125.07M | 14.40 | 24.27% | 27.82% | 35.58% | — | |
| $6.39 | $377.7M | -1.71 | 8.72% | -109.99% | -61.41% | — | |
| $2.32 | $320.82M | -5.52 | -100% | — | -39.75% | — |
Compare ITRM vs Peers
Iterum Therapeutics plc (ITRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ITRM SEC Filings & Documents
Iterum Therapeutics plc (ITRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ITRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ITRM Frequently Asked Questions
Iterum Therapeutics plc (ITRM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Iterum Therapeutics plc's revenue?
Iterum Therapeutics plc (ITRM) reported $0.4M in revenue for fiscal year 2024.
Is ITRM profitable?
Iterum Therapeutics plc (ITRM) reported a net loss of $27.0M for fiscal year 2024.
Dividend & Returns
What is Iterum Therapeutics plc's free cash flow?
Iterum Therapeutics plc (ITRM) had negative free cash flow of $19.9M in fiscal year 2024, likely due to heavy capital investments.